keyword
MENU ▼
Read by QxMD icon Read
search

adherence treatment schizophrenia

keyword
https://www.readbyqxmd.com/read/28614899/determination-of-plasma-concentration-reference-ranges-for-risperidone-and-paliperidone
#1
Julia Korell, Bruce Green, Bart Remmerie, An Vermeulen
Schizophrenia is a common disease managed by a range of interventions with the primary treatment being antipsychotic medications (APS). Inadequate response, lack of adherence, and/or adverse events often prevent optimal therapeutic effects or therapeutic efficiency. Monitoring APS plasma concentrations can be used together with a full clinical evaluation to help improve patient care or offer better treatment options for the patient. To enable interpretation of individual risperidone and paliperidone plasma concentrations, we developed 'reference ranges', which consider the expected variability in plasma concentrations between subjects across the population, rather than representing a 'therapeutic range' that relates to efficacy and/or safety outcomes...
June 14, 2017: CPT: Pharmacometrics & Systems Pharmacology
https://www.readbyqxmd.com/read/28613384/communication-skills-training-for-mental-health-professionals-working-with-people-with-severe-mental-illness
#2
REVIEW
Alexia Papageorgiou, Yoon K Loke, Michelle Fromage
BACKGROUND: Research evidence suggests that both mental health professionals and people with severe mental health illness such as schizophrenia or schizoaffective disorder find it difficult to communicate with each other effectively about symptoms, treatments and their side effects so that they reach a shared understanding about diagnosis, prognosis and treatment. Effective use of communication skills in mental health interactions could be associated with increased patient satisfaction and adherence to treatment...
June 13, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28612979/research-and-practice-for-ultra-high-risk-for-psychosis-a-national-survey-of-early-intervention-in-psychosis-services-in-england
#3
Helen J Stain, Lauren Mawn, Stephanie Common, Marie Pilton, Andrew Thompson
BACKGROUND: Evidence from meta-analyses of randomized clinical trials show interventions for young people at ultra-high risk (UHR) of developing psychosis are effective both clinically and economically. While research evidence has begun to be integrated into clinical guidelines, there is a lack of research on the implementation of these guidelines. This paper examines service provision for UHR individuals in accordance with current clinical guidelines within the National Health Service (NHS) in England...
June 14, 2017: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/28596830/the-effect-of-switching-from-oral-low-dose-aripiprazole-to-aripiprazole-once-monthly-300-mg-on-the-quality-of-life-in-three-patients-with-schizophrenia
#4
Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Hideo Matsumoto, Katsunaka Mikami
BACKGROUND: Schizophrenia is a chronic disease that requires long-term management with antipsychotics; however, an important barrier to the success of long-term treatment is drug noncompliance, which increases the risk of recurrence and hospitalization. Second-generation long-acting injectable antipsychotics have improved drug adherence, and the pharmacological effects of the drugs, and therefore, have become useful treatment options. METHODS: We report on three schizophrenia patients who switched from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg...
2017: SAGE open medical case reports
https://www.readbyqxmd.com/read/28595147/predictors-of-treatment-response-and-drop-out-in-the-treatment-of-early-onset-schizophrenia-spectrum-disorders-teoss-study
#5
Daniel Gabriel, Ewgeni Jakubovski, Jerome H Taylor, Bekir B Artukoglu, Michael H Bloch
The Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) compared the efficacy of risperidone, olanzapine, and molindone over 8 weeks in 119 youths age 8-19 years with early-onset schizophrenia or schizoaffective disorder. From this large dataset, we examined predictors of treatment response and drop out using stepwise regression and receiver operating characteristics curve (ROC) analysis. Treatment response was defined as having both a ≥ 20% improvement in Positive and Negative Syndrome Scale (PANSS) score and a Clinical Global Impression-Improvement (CGI-I) score < 3...
May 30, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28594264/treatment-response-and-tolerability-with-once-monthly-paliperidone-palmitate-initiated-shortly-after-hospital-admission-in-patients-with-schizophrenia
#6
Ludger Hargarter, Marjolein Lahaye, Pierre Cherubin, Martin Lambert, Marnina Swarz, Gali Joldygulov, Flavio Vischia, Veronica Chomskaya, Vasilis P Bozikas, Eva-Maria Tsapakis, Andreas Schreiner
OBJECTIVES: Partial or non-adherence in patients with schizophrenia is common and increases the risk of relapse. This study explored safety, tolerability and treatment outcomes in patients hospitalised for an exacerbation of schizophrenia initiated on maintenance treatment of once-monthly paliperidone palmitate (PP1M). METHODS: A 6-week, observational cohort study of patients initiated on PP1M within 3 weeks after hospital admission. RESULTS: Overall, 367 patients were documented, 85...
June 8, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/28576133/adherence-healthcare-resource-utilization-and-medicaid-spending-associated-with-once-monthly-paliperidone-palmitate-versus-oral-atypical-antipsychotic-treatment-among-adults-recently-diagnosed-with-schizophrenia
#7
Dominic Pilon, Erik Muser, Patrick Lefebvre, Rhiannon Kamstra, Bruno Emond, Kruti Joshi
BACKGROUND: Once-monthly paliperidone palmitate (PP1M) is a long-acting injectable antipsychotic that may increase adherence rates, reduce hospitalizations, and lower medical costs compared to oral atypical antipsychotics (OAAs) among schizophrenia patients. However, the impact of PP1M in recently diagnosed patients remains unknown. The present study compared adherence, healthcare resource utilization and Medicaid spending between schizophrenia patients initiating PP1M versus OAA, among patients recently diagnosed (defined using ages 18-25 years as a proxy) and among the overall population...
June 2, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28566027/perceived-autonomy-support-in-the-nimh-raise-early-treatment-program
#8
Julia Browne, David L Penn, Daniel J Bauer, Piper Meyer-Kalos, Kim T Mueser, Delbert G Robinson, Jean Addington, Nina R Schooler, Shirley M Glynn, Susan Gingerich, Patricia Marcy, John M Kane
OBJECTIVE: This study examined perceived support for autonomy-the extent to which individuals feel empowered and supported to make informed choices-among participants in the Recovery After an Initial Schizophrenia Episode Early Treatment Program (RAISE ETP). The aims of this study were to evaluate whether NAVIGATE, the active treatment studied in RAISE ETP, was associated with greater improvements in perceived autonomy support over the two-year intervention, compared with community care, and to examine associations between perceived autonomy support and quality of life and symptoms over time and across treatment groups...
June 1, 2017: Psychiatric Services: a Journal of the American Psychiatric Association
https://www.readbyqxmd.com/read/28543089/treatments-for-people-living-with-schizophrenia-in-sub-saharan-africa-an-adapted-realist-review
#9
REVIEW
S Chidarikire, M Cross, I Skinner, M Cleary
AIM: To identify the treatments and interventions available and their impact on people living with schizophrenia in Sub-Saharan Africa. BACKGROUND: Help-seeking behaviour and the choice of treatment are largely influenced by socio-cultural factors and beliefs about the causes of mental illness. This review addresses the gap in knowledge regarding the treatment options available to people living with schizophrenia in Sub-Saharan Africa. DESIGN: Adapted realist literature review...
May 25, 2017: International Nursing Review
https://www.readbyqxmd.com/read/28533580/olanzapine-induced-neuroleptic-malignant-syndrome
#10
Seyedhamze Hosseini, Forouzan Elyasi
Neuroleptic malignant syndrome (NMS) is a rare but life-threatening idiosyncratic side effect resulting from neuroleptic drugs. NMS mainly occurs in patients treated with high-potency typical antipsychotics, but rarely caused by atypical antipsychotics. Although NMS is less common with atypical antipsychotic, but it seems that its incidence is rising due to increased administration of such drugs. We present the case of a 27-year-old man with a history of paranoid schizophrenia that showed signs consistent with NMS that occurred after treatment with olanzapine...
May 2017: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/28529220/clinical-correlates-of-treatment-response-among-patients-with-schizophrenia-in-a-tertiary-nigerian-hospital
#11
Mark Sunday Ezeme, Richard Uwakwe, Appolos Chidi Ndukuba, Monday N Igwe, Paul Chigozie Odinka, Kennedy Amadi, Nichodemus O Obayi
A significant proportion of patients treated for schizophrenia respond poorly to medication. Few studies have systematically examined the impact of clinical characteristics of patients to antipsychotic response in our environment. The study aimed to identify clinical variables associated with response in patients with schizophrenia. A total of 172 participants diagnosed with schizophrenia, placed on antipsychotics, who presented for the first time to the hospital or have stopped medication in the preceding six months, whose responses were assessed after four to six weeks were studied...
2017: Journal of Health Care for the Poor and Underserved
https://www.readbyqxmd.com/read/28523839/algorithm-based-pharmacotherapy-for-first-episode-schizophrenia-involuntarily-hospitalized-a-retrospective-analysis-of-real-world-practice
#12
Bunta Yoshimura, Kojiro Sato, Manabu Takaki, Norihito Yamada
BACKGROUND: Little is known about the clinical outcomes of severely ill patients with first-episode schizophrenia spectrum disorders (FES) who are considered to lack the capacity to consent to clinical trials. We investigated the feasibility of an algorithm-based pharmacotherapy (ABP) and clinical outcomes of patients with FES involuntarily hospitalized and treated with ABP. METHODS: We conducted a retrospective chart review of 160 patients admitted involuntarily between October 2012 and October 2015...
May 19, 2017: Early Intervention in Psychiatry
https://www.readbyqxmd.com/read/28470156/-effects-of-a-relapse-prevention-program-on-insight-empowerment-and-treatment-adherence-in-patients-with-schizophrenia
#13
Jaewon Joung, Sungjae Kim
PURPOSE: The purpose of this study was to develop a relapse prevention program (RPP) and examine the effects of the RPP on insight, empowerment, and treatment adherence in patients with schizophrenia. METHODS: A non-equivalent control group pretest-posttest design was used. Participants were 54 inpatients who had a diagnosis of schizophrenia (experimental group: 26, control group: 28). The study was carried out from February 7, 2012 to February 6, 2013. Over a 10-day period prior to discharge each participant in the experimental group received three one-hour sessions of RPP a one-to-one patient-nurse interaction...
April 2017: Journal of Korean Academy of Nursing
https://www.readbyqxmd.com/read/28464848/experiences-perspectives-and-priorities-of-people-with-schizophrenia-spectrum-disorders-regarding-sleep-disturbance-and-its-treatment-a-qualitative-study
#14
Sophie Faulkner, Penny Bee
BACKGROUND: Sleep problems are very common in people with schizophrenia spectrum disorders, and impact negatively on functioning and wellbeing. Research regarding interventions to improve sleep in this population has been lacking. Little is known regarding these patient's perspectives on sleep problems and their treatment, providing very little foundation on which to develop acceptable and patient-centred treatments. METHODS: This study aims to explore perspectives and priorities of participants with schizophrenia spectrum disorders regarding sleep and sleep disturbance, and their perspectives on existing treatments...
May 2, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28463346/an-algorithmic-approach-to-the-management-of-insomnia-in-patients-with-schizophrenia
#15
Ridha Joober, Katherine Cole, Karim Tabbane, Diane B Boivin
BACKGROUND: Insomnia is an important problem in patients with schizophrenia and is an emerging area of interest for researchers. We propose a treatment algorithm that synthesizes the various psychological and pharmacological interventions for insomnia in this population. METHODS: Our selective literature review incorporates English language articles from 4 medicine databases through May 2016. Selected articles discuss risk factors and treatments for insomnia, as well as comorbid sleep disorders that coexist in this population...
May 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/28449560/assessment-of-the-latent-adverse-events-of-antipsychotic-treatment-using-a-subjective-questionnaire-in-japanese-patients-with-schizophrenia
#16
Masakazu Hatano, Hiroyuki Kamei, Azusa Kato, Ippei Takeuchi, Manako Hanya, Junji Uno, Shigeki Yamada, Kiyoshi Fujita, Nakao Iwata
Objective: The adverse effects of antipsychotic agents can have a marked influence on medication adherence. In this study, we. investigated the adverse events of antipsychotics that are less likely to be reported by patients and the reasons why such symptoms remain latent. Methods: Data were collected by interviewing patients using a subjective questionnaire, and the associations between unreported symptoms and background factors were investigated. Results: A total of 306 patients with schizophrenia or schizoaffective disorder were examined...
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28395674/antipsychotic-treatment-resistance-in-first-episode-psychosis-prevalence-subtypes-and-predictors
#17
A Demjaha, J M Lappin, D Stahl, M X Patel, J H MacCabe, O D Howes, M Heslin, U A Reininghaus, K Donoghue, B Lomas, M Charalambides, A Onyejiaka, P Fearon, P Jones, G Doody, C Morgan, P Dazzan, R M Murray
BACKGROUND: We examined longitudinally the course and predictors of treatment resistance in a large cohort of first-episode psychosis (FEP) patients from initiation of antipsychotic treatment. We hypothesized that antipsychotic treatment resistance is: (a) present at illness onset; and (b) differentially associated with clinical and demographic factors. METHOD: The study sample comprised 323 FEP patients who were studied at first contact and at 10-year follow-up...
April 11, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28382557/long-acting-injectable-antipsychotics-in-schizophrenia-literature-review-and-practical-perspective-with-a-focus-on-aripiprazole-once-monthly
#18
REVIEW
Enrico Biagi, Enrico Capuzzi, Fabrizia Colmegna, Alessandra Mascarini, Giulia Brambilla, Alessandra Ornaghi, Jacopo Santambrogio, Massimo Clerici
INTRODUCTION: Prevention of relapse is a major challenge in schizophrenia, a disease characterized by poor adherence to antipsychotic medication leading to multiple rehospitalizations and a substantial burden-of-care. METHODS: We narratively review published clinical data from the development of long-acting injectable (LAI) formulations of antipsychotic drugs and examine the comparative effectiveness of oral versus LAIs in schizophrenia, with a focus on the second-generation LAI antipsychotic aripiprazole...
May 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28374699/-comparative-evaluation-of-clinical-and-economic-efficiency-of-paliperidone-in-various-dosage-forms-used-in-patients-with-schizophrenia
#19
I N D'yakov, S K Zyryanov
AIM: To evaluate clinical and economic efficacy of schizophrenia treatment with three forms of paliperidone (peroral form, intramuscular injections once a month and once in three month). MATERIAL AND METHODS: Pharmacoeconomic analysis based on the results of earlier foreign randomized clinical studies on paliperidone in treatment of schizophrenia was carried out. Indirect comparison of different medication forms of paliperidone compared to placebo was performed...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28356723/treatment-patterns-in-medicaid-patients-with-schizophrenia-initiated-on-a-first-or-second-generation-long-acting-injectable-versus-oral-antipsychotic
#20
Dominic Pilon, Kruti Joshi, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon L Kamstra, Bruno Emond, Patrick Lefebvre
BACKGROUND: Poor antipsychotic (AP) adherence is a key issue in patients with schizophrenia. First-generation antipsychotic (FGA) and second-generation antipsychotic (SGA) long-acting injectable therapies (LAI) may improve adherence compared to oral antipsychotics (OAP). The objective of the study was to compare treatment adherence and persistence in Medicaid patients with schizophrenia initiated on first-generation long-acting injectable therapies (FGA-LAI) or second-generation long-acting injectable therapies (SGA-LAI) versus OAP...
2017: Patient Preference and Adherence
keyword
keyword
110266
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"